Literature DB >> 17410437

Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway.

Akira Yasuda1, Hirozumi Sawai, Hiroki Takahashi, Nobuo Ochi, Yoichi Matsuo, Hitoshi Funahashi, Mikinori Sato, Yuji Okada, Hiromitsu Takeyama, Tadao Manabe.   

Abstract

In this study, we examined the role of c-kit receptor (KIT) signal transduction on the proliferation and invasion of colorectal cancer cells. We found that c-kit was expressed in 2 colorectal cancer cell lines as determined by RT-PCR, Western blot, and flow cytometry. In KIT-positive lines, KIT was activated by stem cell factor (SCF). SCF enhanced cellular proliferation of positive lines as demonstrated by the WST-1 proliferation assay. Furthermore, SCF enhanced the invasive ability of KIT-positive cell lines. SCF stimulation upregulated p44/42 mitogen-activated protein kinase (MAPK) and Akt as shown by Western blot. We examined the roles played by p44/42 MAPK and phosphatidylinositol 3-kinase (PI3K)/Akt pathways in proliferation and invasion. PI3K/Akt activity strongly correlated with proliferation and invasion and p44/42 MAPK was correlated with only invasion. In conclusion, the SCF-enhanced proliferation and invasion of KIT-positive colorectal cancer cells is achieved mainly through the PI3K/Akt pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410437     DOI: 10.1007/s10620-007-9759-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

Review 1.  Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.

Authors:  Siu-Fun Wong
Journal:  Clin Ther       Date:  2005-06       Impact factor: 3.393

2.  The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus.

Authors:  E Huang; K Nocka; D R Beier; T Y Chu; J Buck; H W Lahm; D Wellner; P Leder; P Besmer
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

3.  Identification of a ligand for the c-kit proto-oncogene.

Authors:  D E Williams; J Eisenman; A Baird; C Rauch; K Van Ness; C J March; L S Park; U Martin; D Y Mochizuki; H S Boswell
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

Review 4.  Tyrosine kinase inhibition: an approach to drug development.

Authors:  A Levitzki; A Gazit
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

Review 5.  Kit as a human oncogenic tyrosine kinase.

Authors:  Y Kitamura; S Hirotab
Journal:  Cell Mol Life Sci       Date:  2004-12       Impact factor: 9.261

6.  Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis.

Authors:  Mohtashim Naeem; Madhu Dahiya; Joseph I Clark; Steven D Creech; Serhan Alkan
Journal:  Hum Pathol       Date:  2002-12       Impact factor: 3.466

7.  Elevated SCF levels in the serum of patients with chronic renal failure.

Authors:  T Kitoh; H Ishikawa; T Ishii; S Nakagawa
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

8.  Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis.

Authors:  P Blume-Jensen; L Claesson-Welsh; A Siegbahn; K M Zsebo; B Westermark; C H Heldin
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

Review 9.  Anti-angiogenic strategies in gastrointestinal malignancies.

Authors:  Jonathan Whisenant; Emily Bergsland
Journal:  Curr Treat Options Oncol       Date:  2005-09

10.  Effects of STI571 (gleevec) on pancreatic cancer cell growth.

Authors:  Junsheng Li; Jörg Kleeff; Junchao Guo; Lars Fischer; Nathalia Giese; Markus W Büchler; Helmut Friess
Journal:  Mol Cancer       Date:  2003-09-17       Impact factor: 27.401

View more
  25 in total

1.  IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines.

Authors:  Qinglin Liu; Gang Li; Ronghui Li; Jie Shen; Qiaowei He; Lin Deng; Cai Zhang; Jian Zhang
Journal:  J Neurooncol       Date:  2010-04-02       Impact factor: 4.130

Review 2.  Lung cancer biomarkers, targeted therapies and clinical assays.

Authors:  Jai N Patel; Jennifer L Ersek; Edward S Kim
Journal:  Transl Lung Cancer Res       Date:  2015-10

3.  Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.

Authors:  Vera Levina; Adele Marrangoni; Tingting Wang; Simul Parikh; Yunyun Su; Ronald Herberman; Anna Lokshin; Elieser Gorelik
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

4.  Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth.

Authors:  Leandro E Mainetti; Xiaoning Zhe; Jonathan Diedrich; Allen D Saliganan; Won Jin Cho; Michael L Cher; Elisabeth Heath; Rafael Fridman; Hyeong-Reh Choi Kim; R Daniel Bonfil
Journal:  Int J Cancer       Date:  2014-05-20       Impact factor: 7.396

5.  Novel strategies targeting cancer stem cells through phytochemicals and their analogs.

Authors:  Prasad Dandawate; Subhash Padhye; Aamir Ahmad; Fazlul H Sarkar
Journal:  Drug Deliv Transl Res       Date:  2013-04-01       Impact factor: 4.617

6.  Original Research: Featured Article: Imatinib mesylate (Gleevec) inhibits Notch and c-Myc signaling: Five-day treatment permanently rescues mammary development.

Authors:  Robert Callahan; Barry A Chestnut; Ahmed Raafat
Journal:  Exp Biol Med (Maywood)       Date:  2016-08-21

7.  Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.

Authors:  Sivapriya Ponnurangam; David Standing; Parthasarathy Rangarajan; Dharmalingam Subramaniam
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

8.  Transdifferentiation-inducing HCCR-1 oncogene.

Authors:  Seon-Ah Ha; Hyun K Kim; JinAh Yoo; SangHee Kim; Seung M Shin; Youn S Lee; Soo Y Hur; Yong W Kim; Tae E Kim; Yeun J Chung; Shin S Jeun; Dong W Kim; Yong G Park; Jin Kim; Soon Y Shin; Young H Lee; Jin W Kim
Journal:  BMC Cell Biol       Date:  2010-06-30       Impact factor: 4.241

9.  Lung cancer stem cell: new insights on experimental models and preclinical data.

Authors:  Caroline Rivera; Sofia Rivera; Yohann Loriot; Marie-Catherine Vozenin; Eric Deutsch
Journal:  J Oncol       Date:  2010-12-16       Impact factor: 4.375

10.  KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells.

Authors:  Shu Yang; Wen-shuai Li; Fang Dong; Hai-mei Sun; Bo Wu; Jun Tan; Wan-jing Zou; De-shan Zhou
Journal:  J Cell Mol Med       Date:  2014-09-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.